EcoDrugPlus

Cholinergic Receptor Muscarinic 2

Ensembl ID : ENSBMUG00000014544
Gene Symbol: CHRM2
3 Cross references
261 Possible Orthologues:

Cholinergic Receptor Muscarinic 3

Ensembl ID : ENSBMUG00000008810
Gene Symbol: CHRM3
3 Cross references
257 Possible Orthologues:

Cholinergic Receptor Muscarinic 4

Ensembl ID : ENSBMUG00000022974
Gene Symbol: CHRM4
3 Cross references
186 Possible Orthologues:

Cholinergic Receptor Muscarinic 5

Ensembl ID : ENSBMUG00000016311
Gene Symbol: CHRM5
3 Cross references
264 Possible Orthologues:

Cholinergic Receptor Nicotinic Alpha 3 Subunit

Ensembl ID : ENSBMUG00000003875
Gene Symbol: CHRNA3
3 Cross references
202 Possible Orthologues:

Cholinergic Receptor Nicotinic Alpha 4 Subunit

Ensembl ID : ENSBMUG00000005972
Gene Symbol: CHRNA4
3 Cross references
206 Possible Orthologues:

Cholinergic Receptor Nicotinic Alpha 7 Subunit

Ensembl ID : ENSBMUG00000005369
Gene Symbol: CHRNA7
3 Cross references
249 Possible Orthologues:

Cholinergic Receptor Nicotinic Beta 2 Subunit

Ensembl ID : ENSBMUG00000010899
Gene Symbol: CHRNB2
3 Cross references
198 Possible Orthologues:

Cholinergic Receptor Nicotinic Beta 4 Subunit

Ensembl ID : ENSBMUG00000003926
Gene Symbol: CHRNB4
3 Cross references
199 Possible Orthologues:

Coagulation Factor Ii Thrombin Receptor

Ensembl ID : ENSBMUG00000011164
Gene Symbol: F2R
1 Cross references
330 Possible Orthologues:

Coagulation Factor Ii, Thrombin

Ensembl ID : ENSBMUG00000023372
Gene Symbol: F2
3 Cross references
86 Possible Orthologues:

Coagulation Factor Iii, Tissue Factor

Ensembl ID : ENSBMUG00000026293
Gene Symbol: F3
3 Cross references
246 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).